UH

Umang Hasmukhbhai Patel

Active Director Director DIN 10671355
DIN 10671355 First appointment Jun 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Umang Hasmukhbhai Patel

Data last updated:

Umang Hasmukhbhai Patel is a Director at Zentika Pharma India Private Limited (since 2024). The company operates in Paper.

DIN 10671355
Primary Designation Director
Industry Paper
First Appointment 25 Jun 2024
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zentika Pharma India Private Limited U21009GJ2021PTC126233
Director25 Jun 20242021Active

Board colleagues of Umang Hasmukhbhai Patel

Directorship timeline

Open interactive timeline →
Zentika Pharma India Private Limited
Premium access

Shareholding and investment profile for Umang Hasmukhbhai Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Umang Hasmukhbhai Patel

Umang Hasmukhbhai Patel currently holds 1 directorship: Zentika Pharma India Private Limited (Director, since 25 Jun 2024).

Umang Hasmukhbhai Patel was first appointed on 25 Jun 2024 as Director at Zentika Pharma India Private Limited.

The current boards of Umang Hasmukhbhai Patel's companies include Avinash Dineshbhai Patel (Zentika Pharma India Private Limited), Dharma Bharatbhai Mistry (Zentika Pharma India Private Limited), Priyanka Chaudhary (Zentika Pharma India Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available